Neoadjuvant HER2+

Ipatasertib plus trastuzumab and pertuzumab as frontline maintenance therapy was effective and safe in PIK3CA-mutant, HER2-positive advanced breast cancer.

In case you missed it, below is your guide to the important regulatory approvals made by the FDA in April 2024.

In case you missed any, below is a recap of every episode of OncLive On Air that aired in April 2024.

A chemotherapy-free regimen of trastuzumab plus pertuzumab generated a strong 3-year iDFS rate in patients with HER2-positive early breast cancer.

Tumor intrinsic subtype impacted the association between pCR and EFS after chemotherapy and ERBB2/HER2 blockade in ERBB2/HER2-positive early breast cancer.

MRI-guided treatment could be used to optimize the duration of neoadjuvant chemotherapy in hormone receptor-negative/HER2-positive breast cancer.

Maria Hafez, MD, discusses the design of, and outcomes from, the phase 3 FeDeriCa trial in patients with HER2-positive early breast cancer.

Shruti Tiwari, MD, discusses efforts to address unmet needs through ongoing research in HER2-positive and HER2-low breast cancer.

Shruti Tiwari, MD, discusses treatment sequencing in HER2+ breast cancer, highlighting how to treat these patients when they present with CNS involvement.

Julia Foldi, MD, PhD, discusses the evolving role of treatment with T-DXd in metastatic HER2-positive breast cancer.

Dual HER2-targeted therapy plus checkpoint blockade may offer an effective, tolerable chemotherapy alternative in HER2-positive early breast cancer.

Following preoperative systemic therapy, breast-conserving therapy led to superior OS vs mastectomy in HER2-positive breast cancer.

Rita Nanda, MD, discusses the future of neoadjuvant treatment for patients with HER2-positive breast cancer.

Shruti Tiwari, MD, discusses treatment advances in HER2-positive and HER2-low breast cancer and looks ahead to the future of the space.

Debu Tripathy, MD, discusses the current treatment paradigm of HER2-positive breast cancer and highlights unmet needs that remain.

Reshma L. Mahtani, DO, discusses how the expansion of HER2-targeted agents has impacted the management of HER2-positive breast cancer.

Debu Tripathy, MD, provides insights on the management of HER2-positive breast cancer, including the evolving role of trastuzumab in this population.

Trastuzumab deruxtecan has significant intracranial activity in patients with HER2-positive breast cancer brain metastases, regardless of subgroup.

The UK’s NICE has announced that it will not recommend the use of trastuzumab deruxtecan for the treatment of patients with HER2-low breast cancer.

Sarah Sammons, MD, discusses research efforts in breast cancer focused on HER2-directed therapeutic approaches with central nervous system activity.

Nicholas P. McAndrew, MD, MSCE, discusses the phase 3 HER2CLIMB-02 trial of tucatinib plus trastuzumab emtansine in HER2-positive early breast cancer.

Sarah Sammons, MD, discusses what is known about the incidence of brain metastases in patients with breast cancer.

The ongoing Flamingo-01 trial continues to investigate GLSI-100 in HER2/neu-positive breast cancer following various holds.

Sarah Sammons, MD, discusses the rationale for examining brain metastases in HER2-positive breast cancer, highlighting the implications of recent data.

Nicholas P. McAndrew, MD, MSCE, discusses how updated clinical trial findings are shifting the treatment paradigm in HER2-positive metastatic breast cancer.

Sarah Sammons, MD, discusses the real-world incidence of brain metastases in HER2-positive breast cancer per line of treatment as well as cumulatively.

Maria Hafez, MD, discusses differences in biomarker expression prior to and following neoadjuvant chemotherapy treatment in HER2-positive breast cancer.

Expert oncologists in the field of breast cancer review data in HER2-positive early-stage and metastatic breast cancer.

Nicholas P. McAndrew, MD, MSCE, discusses the implications of the phase 2 PHERGain study of chemotherapy de-escalation in patients with HER2-positive early breast cancer.

Nicholas P. McAndrew, MD, MSCE, discusses the evolution of the treatment armamentarium for HER2-positive breast cancer, including the HER2CLIMB-02 trial.